+1-518-621-2074 | US-Canada Toll Free Contact Us

Novel therapies in Antibacterial Drugs to Treat Diseases Caused by Antibiotic-Resistant Bacteria Unlock Exciting Opportunities

about us

Published on : Feb 28, 2017

ALBANY, NY, Feb 28, 2017: The report on the global antibacterial drugs market provides in-depth insights into the current market status, emerging trends, key product offerings, and major restraints. The research analysis offers an assessment of drug pipeline of prominent manufactures and the impact regulatory landscape has on the market dynamics. The market share and size of major segments are highlighted and the strategies adopted by leading market players to consolidate their market presence in major regions are covered in the report.

The study takes a closer look at prominent developments in vaccine and novel therapies that will have wide ranging impact on competitive dynamics. The growing concern of infections that have antimicrobial resistance has led to the demand for novel therapies in the antibacterial drugs market. This study outlines the key developments related to drugs related to treatment of various ailments such as pneumonia, methicillin-resistant staphylococcus aureus (MRSA), tuberculosis, and sepsis.  Several prophylactic monoclonal antibodies are currently being developed by leading drug makers to gain competitive benefits in the market. 

Prominent antibacterial drugs that are widely used in the treatment of diseases caused by microorganisms are beta-lactam antibiotics that include penicillin. However, over the past few years, the emergence of antibiotic-resistant bacteria has fuelled the demand for modern beta-lactams a combination drugs consisting of a beta-lactam and a beta-lactamase inhibitor. This is expected to spur the demand for antibacterial drugs.

Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=970729

Recent advances in drug making by major pharmaceutical companies have led to the discovery of new classes of drugs, which can treat a wide range of bacterial infections. The market has witnessed the discovery of anti fluoroquinolones that can inhibit DNA gyrase and topoisomerase IV. Another important class of drugs are protein synthesis inhibitors that can inhibit the growth of bacteria that are resistant to various beta-lactam antibiotics. However, a few types of bacteria have become resistant to these drugs leading to large unmet needs in the global antibacterial drugs market. As a result, the market is expected witness more innovations unlocking exciting opportunities for the market players. 

Currently, the antibacterial market is dominated by vaccines, especially those responsible for those for the prevention of diphtheria, pneumococcal infections, tetanus, and pertussis. However, over the forecast period, novel therapies related to inhibition of antibiotic-resistant bacteria offer promising opportunities for market players.

The report offers portfolio analysis of leading drug manufactures and focuses on the marketed and pipeline products. Major market players operating in this market are Pfizer, GlaxoSmithKline, Merck & Co, Allergan, Cempra, Bayer, and Roche

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]